Wednesday, April 22, 2026
33.2 C
Bengaluru

Key Challenges Facing Indian Pharma

Suresh Subramanian, talks about the challenges and way forward for Indian Pharma companies.

Highlights of the discussion:

With the Second Wave hitting India, customers (patients and physicians) will continue to socially distance themselves in the foreseeable future. Pharma must use the field force for reach and relationship and digital for frequency and personalised content for better customer experience.

The pandemic has made doctors adopt Telehealth in a substantial way to shore up their revenues and this will continue to be one of their channels to engage patients. Telehealth along with EMR/EHR, digital therapeutics and wearables is enabling doctors to better care for their patients. There are many ways in which pharma can support the digital evolution of doctors.

Most pharma companies have multiple divisions and the data from these divisions remain in silos and need to be integrated to better understand customers, their needs and build personas that enable wider segmentation for personalisation of communications.

Data will become the New Supervisor and field sales managers will have to transform into Customer Experience Managers and Medical Reps will have to evolve into Media Planners to be able to connect with doctors based on their channel preferences.

As more and more people search the Internet in their efforts to self-manage, Wellness sector will gain momentum and this is where pharma can work with other partners to provide health related information and products via digital channels to people who are online 24×7.

Some questions that Suresh Subramanian will answer in today’s session:

Register now to receive your email invitation – https://www.credoweb.in/discussion/630/key-challenges-facing-pharma-industry-and-the-way-forward

You can listen to 50+ webinars and Q&A sessions by over 20 thought leaders from India and broad on a wide range of topics that impact pharma business.

Hot this week

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy

In 1989, oncology in India was not a business...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

The Healthium Odyssey: From Sutures to Scalpel-Sharp Innovation

The story of Healthium is not just one of...

The 500 Billion Dollar Pill: Why Skipping Medicine Is Costing India a Fortune

In the pharmaceutical world, we often focus on the...

Topics

The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap

The Semaglutide Shift: From Blockbuster to Commodity Why the $50...

Ritesh Desai has joined Standard Chartered India as Executive Director

Ritesh Desai has joined Standard Chartered India as Executive...

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

The Semaglutide Gold Rush: Miracle Cure or Market Mirage?

The Indian Pharmaceutical Market (IPM) has entered a definitive...
spot_img

Related Articles

spot_imgspot_img